Results 101 to 110 of about 210,178 (195)

TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment. [PDF]

Cancer Immunol Res
Pruitt MR, Fabian KP, Lee JM, Hodge JW.
europepmc   +1 more source

Analysis of Risk Factors for Secondary Endometrial Cancer-Related Death: A SEER-Based Study

International Journal of Women's Health
Lianjie Miao, Songwei Feng, Bo Ding, Ke Zhang, Yue Ding, Yang Shen Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People’s Republic of ChinaCorrespondence: Yang Shen, Department of Obstetrics
Miao L, Feng S, Ding B, Zhang K, Ding Y, Shen Y   +5 more
doaj  

The expression and mechanism of action of ADAMTS18 in endometrial cancer. [PDF]

J Mol Histol
Li X, Xu M, Guo X, Xu Y.
europepmc   +1 more source

The impact of the patient macroenvironment on molecular subgroups in endometrial cancer. [PDF]

Cancer
Werner HMJ, van Dijk FAH, Vrede SW, van den Bosch AAS, Lombaers MS, Asberger J, Huvila J, Snijders M, Tubita V, Moreno GM, Matias-Guiu X, Bretová P, ENITEC Consortium, Weinberger V, Pijnenborg JMA.   +14 more
europepmc   +1 more source

MRI and Endometrial Cancer After FIGO 2023-What's New? A Narrative Review. [PDF]

Cancers (Basel)
Gennarini M, Ninkova RV, Miceli V, Curti F, Riccardi S, Gui B, Rizzo S, Venkatesan AM, Nougaret S, Manganaro L.   +9 more
europepmc   +1 more source

Diabetes, Obesity, and Endometrial Cancer: A Review. [PDF]

Curr Oncol
Hooks O, Jhumkhawala V, Sibson K, Shrontz A, Krishnan SS, Ahmad S.   +5 more
europepmc   +1 more source

The clinical impact of androgens in endometrial cancer: cancer promoter or suppressor? [PDF]

Endocr Oncol
Wu X, Tian W, Wang Y.
europepmc   +1 more source

Ureteral Recurrence of the Endometrial Cancer: A Case Report. [PDF]

Case Rep Med
Yuki H, Yokoyama M, Yamaguchi T, Yamaguchi S, Kamai T.   +4 more
europepmc   +1 more source

Soluble immune checkpoints in endometrial cancer - a discovery study. [PDF]

Front Immunol
Pirš B, Pušić MN, Roškar L, Rižner TL, Smrkolj Š.   +4 more
europepmc   +1 more source

POLQ promotes tumor progression and immunosuppression via ATM‑P53 signaling in endometrial cancer. [PDF]

Oncol Rep
Zhu N, Wang J, Zhang X, Tang K, Gong L, Hu Y.   +5 more
europepmc   +1 more source